BAJAJ BROKING

Notification close image
No new Notification messages
card image
Travel Food Services IPO is Open!
Apply for the Travel Food Services IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Dr. Reddy’s US Subsidiary Recalls Drug Quoting Efficacy Issues

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

 Dr Reddy’s Laboratories announces the voluntary recall of six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg in the US due to powder discolouration, leading to decreased potency. Elevated Phenylalaninemia (Phe) levels pose risks of permanent neurocognitive deficits. The company urges consumers to contact physicians and return affected lots promptly.

Dr Reddy’s Laboratories Ltd has initiated a voluntary recall of six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg in the U.S. This recall comes as a result of powder discolouration observed in some packets, leading to decreased potency of the medication.

Risk of Congenital Heart Disease

The reduced efficacy of the product poses a risk of elevated Phenylalaninemia (Phe) levels in patients. Chronic elevation of Phe levels, particularly in infants and children, is associated with permanent neurocognitive deficits such as intellectual disability, developmental delay, and seizures.

Moreover, elevated Phe levels during pregnancy, especially in early gestation, may lead to complications such as microcephaly and congenital heart disease.

Dr Reddy’s Lab Response and Recommendations

Dr Reddy’s Laboratories Inc., the US-based subsidiary, has not received any adverse event reports related to this recall. However, consumers are urged to examine their inventory of the affected product and quarantine any recalled lots immediately.

Additional Read: Share Market News

The company advises consumers to consult their physician before discontinuing the use of the medication. Additionally, consumers are instructed to return the recalled product to their place of purchase.

The recall underscores the importance of quality control in pharmaceutical products to ensure the safety and efficacy of medications for patients.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|